1 / 128

Antithrombotic therapy in children

Antithrombotic therapy in children. Dr.K.Mahesh. Introduction. Rising use of Anticoagulant / Antithrombotic drugs among pediatric patients Thromboembolic Disease – “The new Epidemic of Pediatric Tertiary Care Hospitals”. Nowhere more evident than in pediatric cardiac/cardiac surgery patients.

gabi
Download Presentation

Antithrombotic therapy in children

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Antithrombotic therapy in children Dr.K.Mahesh

  2. Introduction • Rising use of Anticoagulant / Antithrombotic drugs among pediatric patients • Thromboembolic Disease – “The new Epidemic of Pediatric Tertiary Care Hospitals”. • Nowhere more evident than in pediatric cardiac/cardiac surgery patients. • In the last decade – vast improvements in surgical techniques,new drugs, new applications,critical and supportive care- resulted in improved survivals. • TE Disease is one the most frequent complications in these ‘survivors’.

  3. Majority of children on primary anticoagulant prophylaxis have underlying CHD/acquired heart disease • Venous thromboembolic disease in children has a mortality of 7% • Morbidity in the form of post-phlebitic syndrome and recurrent venous thrombosis occurs in 20%

  4. Arterial Thromboembolic Disease

  5. Points of discussion • Antithrombotic / Anticoagulant therapy in context of Pediatric Cardiac morbidities. • Biochemical basis of coagulation and factors that influence / modify it. • Specific drugs that regulate coagulation • Recommendations for anticoagulant therapy in specific clinical situations

  6. Indications for Anticoagulant / Antithrombotic therapy in Pediatric Cardiology • Native structural cardiovascular disease • Vavular heart disease • Cardiomyopathies • Surgically altered cardiovascular architecture • BT Shunt, Glenn, Fontan, Norwood • Valve replacements • Post-op / intensive care related issues • Central line, sepsis • Cardiac catheterization and interventions • Prophylaxis • Interventional procedures

  7. How are things different in children compared to adults?

  8. Epidemiolgical differences • High proportion of secondary thrombosis in children with major underlying HD • Role of central venous access devices • Biphasic age difference – highest risk in neonates and Adolescents • Age distribution of major illnesses that require CVA. • Small physical size of blood vessels related to CVA in neonates • Maturation of coagulation system in adolescents

  9. Frequency and type of intercurrent illnesses – makes administration and regulation of oral anticoagulant therapy difficult • Vascular access impacts ability to deliver and monitor AC • GA used in procedures more commonly in children, affecting ability to confirm and monitor thromboembolic disease and therefore therapeutic decisions

  10. The coagulation cascade

  11. Thrombogenesis • Vasospasm • Platelet adhesion • Platelet aggregation • Viscous metamorphosis • Platelet plug • Fibrin reinforcement • Local production of thrombin • Platelet ADP • Thromboxane A2, Prostacyclin (PGI2). • Serotonin • White thrombus, Red thrombus

  12. Drugs that affect coagulation

  13. Indirect Thrombin Inhbitors Heparin Fondaparinux Vitamin K Antagonists Warfarin Coumarinsl Antithrombotics Direct Thrombin inhibitors Hirudin, Bivaluridin Argatroban, Melagatran Ximelagatran Antiplatelet agents Aspirin Dipyridamole , Clopidogrel Ticlopidine

  14. Indirect Thrombin Inhbitors Act on ANTITHROMBIN Vitamin K Antagonists Act via Vit K dependent factors – II, VII, IX, X Direct Thrombin inhibitors Directly bind to Thrombin

  15. Adults Vs Children / Infants

  16. Developmental Haemostasis • Affects frequency, natural history, and response to agents • Global functioning of the haemostatic system is different from adults • Plasma values of many coagulation proteins are different • Qualitative differences in many of the coagulation proteins, especially in neonates • Significant differences in the antithrombotic properties of the vessel wall

  17. Developmental Haemostasis • Antithrombin (AT) levels are physiologically low at birth (0.50 U/ml) • Adult values are reached only after 3 months • Sick preterms have levels less than 0.30 U/ml • Fetal range 0.20-0.37 at 19-38 weeks • Significance : Profound effect on the action of Heparin • Following infancy, thrombin generating capacity increases but remains 25% less than adult capacity throughout childhood • In-vitro tests show both increased sensitivity and resistance to Unfractionated Heparin (UFH) in neonates

  18. Developmental Haemostasis • Infants have physiologically low levels of Vit K –dependent factors and contact factors which gradually rise to adult values nearing 6 months • Levels of Protein C and Protein S are very low at birth • Interaction of Protein C with Protein S in newborn plasma may be regulated by increased concentration of alpha-2 macroglobulin • Plasma concentration of thrombomodulin is increased in early childhood, decreasing to adult values by teenage • Free tissue factor pathway inhibitor (TFPI) concentrations are significantly lower in neonates

  19. Pharmacokinetic differences • Distribution, binding and clearance of AC agents is age-dependent • Larger volume of distribution, faster clearance of UFH, LMWH in newborns • Altered heparin binding (unproved) • Low levels AT • Result : Higher initial dose of Heparin needed to attain therapeutic levels • Maintenance doses required are highest in infants < 2 months • Higher patient-patient variability • Warfarin doses are also age dependent – reasons not known

  20. Drug formulations • No specific pediatric formulations available Dietary differences • Vit K concentrations in breast milk and infant formulae differ • Breast fed babies are very sensitive to VKA • Formula-fed babies need high doses, increasing the risk of bleeding in case of intercurrent illnesses etc

  21. There are numerous studies defining appropriate strategies in adults with a range of TEs • Anticoagulation strategies are controversial and unproven in children • Attempt to formulate a consensus – 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence based Guidelines

  22. Specific DrugsHeparins

  23. Heparin • A heterogenous mixture of glycosaminoglycans ranging from 3000 to 30000 daltons in MW • Non-branching, negatively charged pentasachharide chain • Pentasachharide sub-unit structure is instrumental in its ability to bind to Antithrombin

  24. Heparin – Mechanism of Action • Indirect thrombin inhibitor • Catalysis the action of Antithrombin by over 1000-fold. • (AT inhibits Thrombin i.e IIa, IXa,and Xa) • Active Heparin molecules bind tightly to AT, causing conformational changes, exposure of its active site for more rapid interaction with the activated clotting factors). • Once AT-protease complex is formed, Heparin is released intact for binding to more AT. • Prevents additional thrombus accretion • Does not lyse a thrombus already formed

  25. HMW fraction of Heparin inhibits all three – thrombin (Factor IIa), IXa and Xa, esplly thrombin and Xa. • LMWH inhibits activated factor X but has less effect on thrombin than HMW species. • Commercial heparin consists of a family of molecules of different MW. • Commercial heparin is extracted from porcine intestinal mucosa and bovine lung. • Usually sodium or calcium salts. Lithium salt for in-vitro anticoagulation. • UFH dosing in in USP units/mg

  26. Therapeutic range of UFH • That reflects a heparin level by protamine titration of 0.2 – 0.4 U/ml or an Anti Factor Xa level of 0.35 – 0.7 U/ml • aPTT therapeutic ranges are universally calculated using adult plasma and are extrapolated onto the pediatric population as well. Validity yet unknown. • In pediatric patients, aPTT values correctly predict therapeutic concentrations approx 70% of the time

  27. Pharmacokinetics and Dose • Volume of distribution is more and clearance rapid in neonates and young infants + heparin binding may also be different. • So higher dose required to achieve adult therapeutic range • Bolus dose of 75 – 100 U/Kg results in therapeutic aPTT value in nearly 90%. • Maintenance is age-dependent • Infants < 2 mo 28U/kg/Hr • Children > 1 yr 20U/kg/Hr • Older children 18U/kg/Hr

  28. Heparin Dosing Nomogram

  29. Adverse effects of Heparin • Bleeding – Andrew M et al reported 1.5% incidence in their prospective cohort study in children treated for DVT/pulmonary embolism • Thrombocytopenia • Non-immune HAT (HIT Type I) • Immune mediated (HIT Type II) • Osteoporosis and spontaneous fractures • Allergic reactions • Reversible alopecia • Long-term usage : mineralocorticoid deficiency

  30. Frequency of HIT

  31. Treatment of adverse affects • Bleeding: Cessation of heparin and IV Protamine if needed

  32. Treatment of thrombocytopenia • Non-Immune HAT : Promptly discontinue Heparin • Suspected HIT : • Discontinue all Heparin • Confirm diagnosis with alternate tests • Alternative anticoagulants • Monitor for thrombosis and platelet counts • Avoid prophylactic platelet transfusion

  33. Treatment of HIT • Stop Heparin • Alternative anticoagulants • Warfarin: disadvantage- takes 4-5 days for full therapeutic effect ; associated with venous limb gangrene when used alone • LMWH • Recombinant Hirudin, • Danaparoid sodium • Ancrod (isolated from Malayan Viper) • Prostacyclin analogues • IVIG • Plasmapharesis

  34. Low Molecular Weight Heparins(LMWH) • Principally inhibit Factor X, less effect on Thrombin • Enoxaparin: same source as regular heparin, but doses specified in mg • Dalteparin , Tinzaparin, Danaparoid (a mixture of heparan sulfate, dermatan sulfate and chondroitin sufate):doses specified in Anti Factor Xa units

  35. Low Molecular Weight Heparins • Have rapidly become AC of choice in many pediatric patients both for primary prophylaxis, and treatment of TE, despite unproven efficacy • Advantages • Need for minimal monitoring • Lack of interference by other drugs or diet (as for VKAs) • Reduced risk of HIT • Reduced risk of Osteoprosis • Disadvantages • High in-vitro cross-reactivity with Heparin dependent antibodies • Significant risk of recurrent or progressive thrombocytopenia and/or thrombosis • Reduced predictability of anticoagulant effect compared to adults

  36. LMWH – Therapeutic range and dosage • Extrapolated from adult data, based on Anti Factor Xa levels – 0.50 – 1.0 U/ml in a sample taken 4-6 hours following a subcutaneous inj • Peak occurs 2-6 hours after s/c inj • < 2-3 months or <5 Kg have higher requirement due to increased volume of distribution, lower levels of AT and or altered heparin pharmacokinetics

  37. L M W H D O S A G E

  38. Adverse effects of LMWH • Dix D et al reported 10.8% major bleeding complication in infants in a prospective cohort study • Same authors reported bleeding complication in 4.8% patients with enoxaparin • Massicotte P et al reported major bleeding complications in 8.1% patients in a randomized trial, with Reviparin • No data on frequency of osteoporosis, HIT, hypersensitivity reactions in children • TREATMENT: Protamine Sulfate

  39. Contra-indications to Heparin • Hypersensitivity • Active bleeding • Hemophillia • Significant thrombocytopenia/purpura • Severe hypertension • ICH • IE • Active TB • Ulcerations of GI tract • Threatened abortion • Visceral Ca • Advanced hepatic or renal disease • AVOID IN : Recent neuro/ophthalmic surgery, or undergoing lumbar puncture / regional anaesthetic block, pregnancy

  40. Vitamin K Antagonists

  41. Vitamin K Antagonists – Warfarin and coumarin anticoagulants • Discovery of an anticoagulant substance ( bishydroxycoumarin ) formed in spoiled sweet clover silage which resulted in hemorrhagic disease in cattle. • Warfarin is the most reliable member of this group, which also comprises Dicumarol,Phenprocoumon,Phenindione, Diphenindione

  42. Warfarin generally administered as a Sodium salt • 100% bio-availability • 99% bound to albumin, small volume of distribution • Long plasma half life – 36 hours • Racemic mixture of levorotatory S-warfarin (4 times more potent) and dextrorotatory R-warfarin

  43. MOA of Warfarin • Blocks gamma carboxylation of several glutamate residues in Prothrombin and factors VII, IX, X and endogenous anticoagulant proteins C and S : results in biologically inactive molecules • Oxidative deactivation of Vit K. Prevents reductive metabolism of inactive Vit K epoxide back to its active hydroxyquinolone form

More Related